Effect of testosterone on markers of mitochondrial oxidative phosphorylation and lipid metabolism in muscle of aging men with subnormal bioavailable testosterone

European Journal of Endocrinology

Volumn 171, Issue 1, 2014, Pages 77-88

  Petersson, Stine J ^a,b   Christensen, Louise L ^b   Kristensen, Jonas M ^a,b   Kruse, Rikke ^a,b   Andersen, Marianne ^b   Højlund, Kurt ^a,b  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MESSENGER RNA; MITOCHONDRIAL DNA; MITOGEN ACTIVATED PROTEIN KINASE P38; PLACEBO; TESTOSTERONE;

ACADVL GENE; ADULT; AGED; AGING; ANDROGEN THERAPY; ARTICLE; CALORIMETRY; CD36 GENE; CLAMP; CONTROLLED STUDY; COX5B GENE; CPT1B GENE; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; ETFA GENE; EUGLYCEMIC HYPERINSULINEMIC CLAMP; GENETIC CODE; HADH GENE; HUMAN; HUMAN TISSUE; INSULIN SENSITIVITY; LIPID METABOLISM; LIPID OXIDATION; MALE; MITOCHONDRIAL GENE; MITOCHONDRION; MUSCLE BIOPSY; NDUFS1 GENE; OXIDATIVE PHOSPHORYLATION; PDK4 GENE; PPARGC1A GENE; PRIORITY JOURNAL; PRKAA2 GENE; PRKAG3 GENE; PROTEIN LOCALIZATION; RANDOMIZED CONTROLLED TRIAL; REAL TIME POLYMERASE CHAIN REACTION; SDHA GENE; SKELETAL MUSCLE; TESTOSTERONE BLOOD LEVEL; UQCRC1 GENE; WESTERN BLOTTING;

AGING; BLOTTING, WESTERN; BODY COMPOSITION; ELECTROPHORESIS, POLYACRYLAMIDE GEL; LIPID METABOLISM; MUSCLE, SKELETAL; OXIDATIVE PHOSPHORYLATION; REAL-TIME POLYMERASE CHAIN REACTION; TESTOSTERONE;

EID: 84903532634     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-14-0006     Document Type: Article

References (46)

1. Grossmann M. Low testosterone in men with type 2 diabetes: significance and treatment. Journal of Clinical Endocrinology and Metabolism 2011 96 2341-2353. (doi:10.1210/jc.2011-0118)
2. Zitzmann M. Testosterone deficiency, insulin resistance and the metabolic syndrome. Nature Reviews. Endocrinology 2009 5 673-681. (doi:10.1038/nrendo. 2009.212)
3. Dubois V, Laurent M, Boonen S, Vanderschueren D & Claessens F. Androgens and skeletal muscle: cellular and molecular action mechanisms underlying the anabolic actions. Cellular and Molecular Life Sciences 2012 69 1651-1667. (doi:10.1007/s00018-011-0883-3)
4. Frederiksen L, Hojlund K, Hougaard DM, Brixen K & Andersen M. Testosterone therapy increased muscle mass and lipid oxidation in aging men. Age 2012 34 145-156. (doi:10.1007/s11357-011-9213-9)
5. Grossmann M, Gianatti EJ & Zajac JD. Testosterone and type 2 diabetes. Current Opinion in Endocrinology, Diabetes, and Obesity 2010 17 247-256. (doi:10.1097/MED.0b013e32833919cf)
6. Hojlund K & Beck-Nielsen H. Impaired glycogen synthase activity and mitochondrial dysfunction in skeletal muscle: markers or mediators of insulin resistance in type 2 diabetes? Current Diabetes Reviews 2006 2 375-395. (doi:10.2174/1573399810602040375)
7. Hojlund K, Mogensen M, Sahlin K & Beck-Nielsen H. Mitochondrial dysfunction in type 2 diabetes and obesity. Endocrinology and Metabolism Clinics of North America 2008 37 713-731. (doi:10.1016/j.ecl.2008.06.006)
8. Mogensen M, Sahlin K, Fernstrom M, Glintborg D, Vind BF, Beck-Nielsen H & Hojlund K. Mitochondrial respiration is decreased in skeletal muscle of patients with type 2 diabetes. Diabetes 2007 56 1592-1599. (doi:10.2337/db06- 0981)
9. Petersen KF, Befroy D, Dufour S, Dziura J, Ariyan C, Rothman DL, DiPietro L, Cline GW& Shulman GI. Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science 2003 300 1140-1142. (doi:10.1126/science. 1082889)
10. Szendroedi J, Phielix E & Roden M. The role of mitochondria in insulin resistance and type 2 diabetes mellitus. Nature Reviews. Endocrinology 2012 8 92-103. (doi:10.1038/nrendo.2011.138)
11. Giebelstein J, Poschmann G, Hojlund K, Schechinger W, Dietrich JW, Levin K, Beck-Nielsen H, Podwojski K, Stuhler K, Meyer HE et al. The proteomic signature of insulin-resistant human skeletal muscle reveals increased glycolytic and decreased mitochondrial enzymes. Diabetologia 2012 55 1114-1127. (doi:10.1007/s00125-012-2456-x)
12. Hwang H, Bowen BP, Lefort N, Flynn CR, De Filippis EA, Roberts C, Smoke CC, Meyer C, Hojlund K, Yi Z et al. Proteomics analysis of human skeletal muscle reveals novel abnormalities in obesity and type 2 diabetes. Diabetes 2010 59 33-42. (doi:10.2337/db09-0214)
13. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E, Ridderstrale M, Laurila E et al. PGC-1a-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nature Genetics 2003 34 267-273. (doi:10.1038/ng1180)
14. Patti ME, Butte AJ, Crunkhorn S, Cusi K, Berria R, Kashyap S, Miyazaki Y, Kohane I, Costello M, Saccone R et al. Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: potential role of PGC1 and NRF1. PNAS 2003 100 8466-8471. (doi:10.1073/pnas.1032913100)
15. Lowell BB & Shulman GI. Mitochondrial dysfunction and type 2 diabetes. Science 2005 307 384-387. (doi:10.1126/science.1104343)
16. Cusi K, Maezono K, Osman A, Pendergrass M, Patti ME, Pratipanawatr T, DeFronzo RA, Kahn CR & Mandarino LJ. Insulin resistance differentially affects the PI3-kinase-and MAP kinasemediated signaling in human muscle. Journal of Clinical Investigation 2000 105 311-320. (doi:10.1172/JCI7535)
17. Karlsson HK, Zierath JR, Kane S, Krook A, Lienhard GE & Wallberg-Henriksson H. Insulin-stimulated phosphorylation of the Akt substrate AS160 is impaired in skeletal muscle of type 2 diabetic subjects. Diabetes 2005 54 1692-1697. (doi:10.2337/diabetes.54.6.1692)
18. Vind BF, Pehmoller C, Treebak JT, Birk JB, Hey-Mogensen M, Beck-Nielsen H, Zierath JR, Wojtaszewski JF & Hojlund K. Impaired insulin-induced site-specific phosphorylation of TBC1 domain family, member 4 (TBC1D4) in skeletal muscle of type 2 diabetes patients is restored by endurance exercise-training. Diabetologia 2011 54 157-167. (doi:10.1007/s00125-010-1924-4)
19. Pitteloud N,Mootha VK, Dwyer AA, Hardin M, Lee H, Eriksson KF, Tripathy D, Yialamas M, Groop L, Elahi D et al. Relationship between testosterone levels, insulin sensitivity, andmitochondrial function in men. Diabetes Care 2005 28 1636-1642. (doi:10.2337/diacare.28.7.1636)
20. Birzniece V, Meinhardt UJ, Handelsman DJ & Ho KK. Testosterone stimulates extra-hepatic but not hepatic fat oxidation (Fox): comparison of oral and transdermal testosterone administration in hypopituitary men. Clinical Endocrinology 2009 71 715-721. (doi:10.1111/j.1365-2265.2009.03524.x)
21. Gibney J, Wolthers T, Johannsson G, Umpleby AM & Ho KK. Growth hormone and testosterone interact positively to enhance protein and energy metabolism in hypopituitary men. American Journal of Physiology. Endocrinology and Metabolism 2005 289 E266-E271. (doi:10.1152/ajpendo.00483.2004)
22. Mauras N, Hayes V,Welch S, Rini A, Helgeson K, DoklerM, Veldhuis JD & Urban RJ. Testosterone deficiency in young men: marked alterations in whole body protein kinetics, strength, and adiposity. Journal of Clinical Endocrinology and Metabolism 1998 83 1886-1892.
23. Ibebunjo C, Eash JK, Li C,Ma Q & Glass DJ. Voluntary running, skeletal muscle gene expression, and signaling inversely regulated by orchidectomy and testosterone replacement. American Journal of Physiology. Endocrinology and Metabolism 2011 300 E327-E340. (doi:10.1152/ajpendo.00402. 2010)
24. Salehzadeh F, Rune A, Osler M & Al-Khalili L. Testosterone or 17β-estradiol exposure reveals sex-specific effects on glucose and lipid metabolism in human myotubes. Journal of Endocrinology 2011 210 219-229. (doi:10.1530/JOE-10-0497)
25. Hock MB & Kralli A. Transcriptional control of mitochondrial biogenesis and function. Annual Review of Physiology 2009 71 177-203. (doi:10.1146/annurev.physiol.010908.163119)
26. Nielsen TL, Hagen C,Wraae K, Brixen K, Petersen PH, Haug E, Larsen R & Andersen M. Visceral and subcutaneous adipose tissue assessed by magnetic resonance imaging in relation to circulating androgens, sex hormone-binding globulin, and luteinizing hormone in young men. Journal of Clinical Endocrinology and Metabolism 2007 92 2696-2705. (doi:10.1210/jc.2006-1847)
27. Frederiksen L, Hojlund K, Hougaard DM, Mosbech TH, Larsen R, Flyvbjerg A, Frystyk J, Brixen K & Andersen M. Testosterone therapy decreases subcutaneous fat and adiponectin in aging men. European Journal of Endocrinology 2012 166 469-476. (doi:10.1530/EJE-11-0565)
28. Hother-Nielsen O, Henriksen JE, Holst JJ & Beck-Nielsen H. Effects of insulin on glucose turnover rates in vivo: isotope dilution versus constant specific activity technique. Metabolism 1996 45 82-91. (doi:10.1016/S0026- 0495(96)90204-8)
29. Hojlund K, Frystyk J, Levin K, Flyvbjerg A, Wojtaszewski JF & Beck-Nielsen H. Reduced plasma adiponectin concentrations may contribute to impaired insulin activation of glycogen synthase in skeletal muscle of patients with type 2 diabetes. Diabetologia 2006 49 1283-1291. (doi:10.1007/s00125-006- 0240-5)
30. Frayn KN. Calculation of substrate oxidation rates in vivo from gaseous exchange. Journal of Applied Physiology: Respiratory, Environmental and Exercise Physiology 1983 55 628-634.
31. Vermeulen A, Verdonck L & Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. Journal of Clinical Endocrinology and Metabolism 1999 84 3666-3672. (doi:10.1210/jcem.84.10.6079)
32. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van RoyN,De Paepe A& Speleman F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biology 2002 3. RESEARCH0034. (doi:10.1186/gb-2002-3-7-research0034)
33. Hellemans J, Mortier G, De Paepe A, Speleman F & Vandesompele J. qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data. Genome Biology 2007 8 R19. (doi:10.1186/gb-2007-8-2-r19)
34. Woods A, Salt I, Scott J, Hardie DG & Carling D. The α1 and α2 isoforms of the AMP-activated protein kinase have similar activities in rat liver but exhibit differences in substrate specificity in vitro. FEBS Letters 1996 397 347-351. (doi:10.1016/S0014-5793(96)01209-4)
35. Hardie DG, Ross FA & Hawley SA. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nature Reviews. Molecular Cell Biology 2012 13 251-262. (doi:10.1038/nrm3311)
36. Sanchez AM, Candau RB, Csibi A, Pagano AF, Raibon A &BernardiH. The role of AMP-activated protein kinase in the coordination of skeletal muscle turnover and energy homeostasis. American Journal of Physiology. Cell Physiology 2012 303 C475-C485. (doi:10.1152/ajpcell.00125.2012)
37. Tomas E, Tsao TS, Saha AK, Murrey HE, Zhang CC, Itani SI, Lodish HF & Ruderman NB. Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMPactivated protein kinase activation. PNAS 2002 99 16309-16313. (doi:10.1073/pnas.222657499)
38. Yoon MJ, Lee GY, Chung JJ, Ahn YH, Hong SH & Kim JB. Adiponectin increases fatty acid oxidation in skeletal muscle cells by sequential activation of AMP-activated protein kinase, p38 mitogen-activated protein kinase, and peroxisome proliferator-activated receptor alpha. Diabetes 2006 55 2562-2570. (doi:10.2337/db05-1322)
39. Civitarese AE, Ukropcova B, Carling S, Hulver M, DeFronzo RA, Mandarino L, Ravussin E & Smith SR. Role of adiponectin in human skeletal muscle bioenergetics. Cell Metabolism 2006 4 75-87. (doi:10.1016/j.cmet.2006.05.002)
40. Kadowaki T & Yamauchi T. Adiponectin and adiponectin receptors. Endocrine Reviews 2005 26 439-451. (doi:10.1210/er.2005-0005)
41. Maneschi E, Morelli A, Filippi S, Cellai I, Comeglio P, Mazzanti B, Mello T, Calcagno A, Sarchielli E, Vignozzi L et al. Testosterone treatment improves metabolic syndrome-induced adipose tissue derangements. Journal of Endocrinology 2012 215 347-362. (doi:10.1530/JOE-12-0333)
42. Wang C, Nieschlag E, Swerdloff R, Behre HM, HellstromWJ, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morales A et al. Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. Journal of Andrology 2009 30 1-9. (doi:10.2164/jandrol.108. 006486)
43. Rosner W, Auchus RJ, Azziz R, Sluss PM & Raff H. Position statement: utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. Journal of Clinical Endocrinology and Metabolism 2007 92 405-413. (doi:10.1210/jc.2006-1864)
44. Kapoor D, Clarke S, Stanworth R, Channer KS & Jones TH. The effect of testosterone replacement therapy on adipocytokines and C-reactive protein in hypogonadal men with type 2 diabetes. European Journal of Endocrinology 2007 156 595-602. (doi:10.1530/EJE-06-0737)
45. Page ST, Herbst KL, Amory JK, Coviello AD, Anawalt BD, Matsumoto AM& BremnerWJ. Testosterone administration suppresses adiponectin levels in men. Journal of Andrology 2005 26 85-92.
46. Page ST, Amory JK, Bowman FD, Anawalt BD, Matsumoto AM, Bremner WJ & Tenover JL. Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. Journal of Clinical Endocrinology and Metabolism 2005 90 1502-1510. (doi:10.1210/jc.2004-1933)